Skip to main content
TipRanks
Go Ultimate75% OFF

Ikonisys SA (ALIKO) AI Stock Analysis

1 Followers
FR:ALIKO

Ikonisys SA

(Paris:ALIKO)

Select Model
Rating:44Neutral
Price Target:EUR 1.50â–²(3.45% Upside)
Action:reiterated
Date:08/17/26

The score reflects a high-risk, early-stage profile dominated by persistent operating and cash flow losses despite improving revenue and solid gross margins, only partially mitigated by a conservative, low-leverage balance sheet that provides some resilience; technically the stock shows a soft downward bias without convincing bullish momentum, and with a negative P/E and no dividend, the investment case hinges largely on uncertain future improvements rather than current earnings strength.

Positive Factors
Strong Revenue GrowthThe sharp revenue acceleration indicates improving customer adoption and commercial traction. Sustained growth could expand the installed base and increase future consumables and service revenue, supporting a more scalable recurring-revenue model.
Negative Factors
Large Persistent LossesRevenue growth has not yet translated into operating leverage. Very large, widening losses indicate that fixed costs, development spending, or commercialization expenses remain disproportionate to sales, limiting the credibility of near-term profitability.

Ikonisys SA (ALIKO) vs. iShares MSCI France ETF (EWQ)

-10%-5%0%5%10%15%20%FR:ALIKO+1.05%EWQ+2.16%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 22.89M
Dividend Yield
―
Average Volume (3M)
2,720
Price to Earnings (P/E)
-5.3
Beta (1Y)
0.23
Revenue Growth
37.28%
EPS Growth
7.83%
Country
France
Employees
15
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Ikonisys SA Business Overview & Revenue Model

Company Description

Based in Paris, France, Ikonisys S.A. is a company specializing in cell-based diagnostics. It develops, produces, and commercializes medical diagnostic solutions for various cancers across the United States and Europe. Their core offering includes th...

How the Company Makes Money

Ikonisys SA primarily makes money by selling (1) its diagnostic/cytogenetics instrumentation platforms (automated imaging and analysis systems) and (2) recurring consumables and related products used with those platforms (e.g., assay/reagent kits and...

Ikonisys SA Financial Statement Overview

Summary

Overall financial quality is weak: the income statement is deeply loss-making (income score 32) with net losses about three times revenue and no progress toward breakeven, while cash flow is structurally negative (cash flow score 28), indicating continued cash burn and reliance on external funding; these are only partly offset by a relatively solid, low-leverage balance sheet (score 63) with a sizable equity buffer.

Income Statement

32Negative

Balance Sheet

63Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.01M1.39M1.01M448.56K935.22K365.14K
Gross Profit715.37K897.27K715.37K255.83K751.80K28.46K
EBITDA-1.70M-1.28M-1.77M-927.41K-1.35M-483.65K
Net Income-3.24M-4.20M-3.24M-2.27M-2.45M-571.27K
Balance Sheet
Total Assets27.40M26.71M27.40M20.85M21.72M22.52M
Cash, Cash Equivalents and Short-Term Investments25.08K1.03M25.08K9,40293.98K1.52M
Total Debt4.13M3.25M4.13M3.40M2.51M1.24M
Total Liabilities13.14M7.58M13.14M5.12M4.04M2.50M
Stockholders Equity14.25M19.13M14.25M15.73M17.67M20.01M
Cash Flow
Free Cash Flow0-1.17M-1.37M-1.46M-2.01M-1.36M
Operating Cash Flow0-1.16M-1.33M-914.22K-1.14M-781.42K
Investing Cash Flow0-301.62K-67.58K-545.24K-884.20K-636.56K
Financing Cash Flow02.36M1.41M1.37M599.13K2.90M

Ikonisys SA Technical Analysis

Technical Analysis SentimentPositive
Last Price1.45

Price Trends

50DMA1.41Positive
100DMA1.45Positive
200DMA1.48Negative

Market Momentum

MACD0.00Negative
RSI59.08Neutral
STOCH94.44Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALIKO, the sentiment is Positive. The current price of 1.45 is above the 20-day moving average (MA) of 1.41, above the 50-day MA of 1.41, and below the 200-day MA of 1.48, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 59.08 is Neutral, neither overbought nor oversold. The STOCH value of 94.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALIKO.

Ikonisys SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:ALIKO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:ALERSFR:ALERS58NeutralEUR 259.38M37.713.89%―6.28%204.56%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:ALMKTFR:ALMKT46NeutralEUR 18.02M1.46-157.72%―3.38%―
FR:ALNOVFR:ALNOV45NeutralEUR 32.66M-0.78-159.70%―10.36%29.41%
FR:ALIKOFR:ALIKO44NeutralEUR 22.89M-5.31-22.49%―37.28%7.83%
FR:ALMDTFR:ALMDT43NeutralEUR 213.68M-3.54271.64%―2.16%-5.26%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%FR:ALIKOFR:ALMKTFR:ALNOVFR:ALERSFR:ALDMSFR:ALMDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ALIKO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ALIKOIkonisys SA1.45-0.01-0.68%
FR:ALMKTMAUNA KEA TECHNOLOGIES0.090.019.52%
FR:ALNOVNovacyt S.A.0.450.011.58%
FR:ALERSEurobio-Scientific SA26.401.556.24%
FR:ALDMSDiagnostic Medical Systems0.90-0.38-29.69%
FR:ALMDTMedian Technologies4.361.4047.30%

Ikonisys SA Corporate Events

Aliko Scientific signs Romanian and Saudi distribution deals to boost cancer diagnostics reach

Aug 5, 2026

Aliko Scientific has expanded its international footprint in cancer diagnostics by signing distribution agreements in Romania with Proton Impex 2000 and in Saudi Arabia with H-Care Medical Est., covering its portfolio in liquid-based cytology, FISH,...

Aliko Scientific boosts revenue and advances integrated oncology platform despite wider net loss

Jul 30, 2026

Aliko Scientific reported a 52.6% rise in total revenue to €1.64 million for 2025, driven by the full-year consolidation of Hospitex and the rollout of its integrated oncology diagnostics offering. EBITDA loss narrowed by about a third to €1.14 milli...

Aliko Scientific Subsidiary Hospitex to Study National Urine24 Cancer Screening in Uzbekistan

Jul 23, 2026

Aliko Scientific’s subsidiary Hospitex International has signed an agreement with the Jizzakh branch of Uzbekistan’s Republican Scientific and Practical Centre for oncology and radiology to develop a feasibility study for a national urinary tract can...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026